Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Bristol-Myers Squibb CoBMY-18.132.506.938.84-31.33%-8.05%51.30$57.82-$93.05153,377$58.36

Detail of Bristol-Myers Squibb Co

 
CEO
Dr. Christopher S. Boerner Ph.D.
Employees
34100
Industry
Drug Manufacturers - General
Sector
Healthcare
Market cap
$118B

Company details

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OI
OIE
PI
TAX
NI
Revenue (Rev)
$47.44B
Cost of goods (CoG)
-$11.90B
Gross profit (GP)
$35.53B
Operating expense (OE)
-$18.80B
Research and development (R&D)
-$10.45B
General and administrative (G&A)
-$8.35B
Operating income (OI)
$7.28B
Other income expense (OIE)
-$12.39B
Pretax income (PI)
-$6.88B
Tax (TAX)
-$367.00M
Net income (NI)
-$7.25B
Bristol-Myers Squibb Co
BMY • XNYS • US
$58.36
+8.14 (16.21%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Dividend yield
4.11%
Trailing annual dividend rate
$2.40
Payout ratio
59.84%
EPS
-$3.22
Margin profit
-15.30%
52 week low
$39.66
52 week high
$60.939999
50-day simple moving average
$58.35
200-day simple moving average
$57.82
Percent held by insiders
0.12%
Percent held by institutions
78.41%
Dividend yield
4.12%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
BMY +17.02%
eps change
BMY -36.17%